Bicistronic-CD19/22 Chimeric Antigen Receptor T-Cell Therapy for Childhood Refractory Lupus Nephritis.
Three teenagers with severe lupus kidney disease that had failed several treatments went into remission within three months of receiving engineered immune cells, and stayed off medication for up to 15 months. One developed a severe inflammatory complication that needed intensive treatment.
Background
About 40% of patients with systemic lupus erythematosus progress to lupus nephritis, and refractory disease in children remains difficult to treat after multiple immunosuppressive regimens have failed. Dual-antigen CAR-T targeting is proposed to achieve deeper and more durable B-cell depletion than anti-CD20 antibody therapy.
Study design
Three patients aged 14-17 years with biopsy-confirmed refractory class IV ± III/V lupus nephritis, all of whom had failed multiple immunosuppressive therapies, received autologous bicistronic CD19/22 CAR-T cells following lymphodepleting chemotherapy with fludarabine and cyclophosphamide.
Key findings
All three patients achieved significant clinical remission within three months and maintained drug-free remission across 9-15 months of follow-up. Deep B-cell depletion was achieved within one week of infusion. Mean time to peripheral B-cell reconstitution was 89 ± 32 days, with the reconstituted population predominantly CD27-negative naive B cells and only minimal memory B cells and CD38+CD20- plasmablasts.
Safety
Two patients developed grade 1 cytokine release syndrome. One developed grade 4 cytokine release syndrome complicated by haemophagocytic lymphohistiocytosis and thrombotic microangiopathy, controlled with methylprednisolone, etoposide and eculizumab. The authors emphasise meticulous patient screening before CAR-T administration.
Clinical implications
Paediatric nephrologists now have early evidence that CAR-T can produce drug-free remission in refractory childhood lupus nephritis, but the severe-toxicity case in a three-patient series argues for delivery only in centres equipped to recognise and treat HLH and TMA.
Category
Research
Source
Kidney International Reports
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.